LifeStance Health Group Inc. Common Stock Earnings Recaps
Q3 2025
Nov 6, 2025
LifeStance Health reported a standout third quarter with 17% organic visit growth and record-high adjusted EBITDA margins, reinforcing its robust operational model and strategic positioning in the mental health sector.
Key takeaways
- Revenue reached $364 million, reflecting a 16% year-over-year increase driven by strong visit volumes.
- Achieved adjusted EBITDA of $40 million, marking an 11% margin, the highest since going public in 2021.
- Added a record 288 organic clinicians, bringing the total to nearly 8,000, enhancing patient access and service quality.
- Partnership with Calm expands referral capabilities, enhancing patient pathways to care.
- Full-year guidance for adjusted EBITDA raised, indicating strong confidence in ongoing growth momentum.
Q2 2025
Aug 8, 2025
LifeStance Health delivered strong second-quarter performance with 11% revenue growth, achieving double-digit margins and improved clinician productivity, prompting an increase in full-year adjusted EBITDA guidance.
Key takeaways
- Revenue grew to $345 million, up 11% year-over-year, driven by a 12% increase in visit volume.
- Added 173 clinicians, totaling 7,780, contributing to enhanced service capacity and productivity.
- Achieved adjusted EBITDA of $34 million, with margins expected to remain in the double digits for the year.
- Implemented a clinician cash incentive program and advanced tech initiatives, including AI solutions to improve operational efficiency.
- Strong free cash flow of $57 million, the highest in company history, supports future growth investments.